Laura F. Michael
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Cholesterol and Lipid Metabolism, Drug Transport and Resistance Mechanisms, Lipoproteins and Cardiovascular Health, Cancer, Lipids, and Metabolism, Neonatal Respiratory Health Research
Most-Cited Works
- → Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres(2002)2,506 cited
- → Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1(2001)655 cited
- → Regulation of Carbohydrate Metabolism by the Farnesoid X Receptor(2004)286 cited
- → T0901317 is a dual LXR/FXR agonist(2004)184 cited
- → Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)(2023)183 cited
- → Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation(2023)167 cited
- → A CRE-like sequence that binds CREB and contributes to cAMP-dependent regulation of the proximal promoter of the human aromatase P450 (CYP19) gene(1997)144 cited
- → The Phosphorylation Status of a Cyclic AMP-Responsive Activator Is Modulated via a Chromatin-Dependent Mechanism(2000)104 cited
- → Oral Muvalaplin for Lowering of Lipoprotein(a)(2024)94 cited
- → Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptor(2005)91 cited